When was CroiValve founded?

CroiValve was founded in 2016 and raised its 1st funding round 2 years after it was founded.

Where is CroiValve located?

CroiValve is headquartered in Dublin, Ireland.

Who is the current CEO of CroiValve?

Lucy Okeeffe of CroiValve. They have also founded 1 company.

How many employees does CroiValve have?

As of Aug 31, 2026, the latest employee count at CroiValve is 56.

Is CroiValve a funded company?

CroiValve is a funded company, having raised a total of $52.1M across 13 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on 2018.

When was the latest funding round of CroiValve?

CroiValve's latest funding was a $***** Grant (prize money) round on Jun 23, 2026, with participation from 2 investors.

Where does CroiValve rank among its competitors?

CroiValve ranks 7th amongst 109 active competitors, of which 49 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was CroiValve, which secured $20M in Jun, 2026.

CroiValve - 2026 Company Profile, Team, Funding & Competitors

Q: Who are the top competitors of CroiValve?

CroiValve's top competitors include Shockwave Medical, Cardiac Dimensions and MicroPort CardioFlow Medtech Corporation. Among them, CroiValve secured the most recent funding round in June, 2026.

CroiValve is a series B company based in Dublin (Ireland), founded in 2016 by Martin Quinn and Lucy Okeeffe. It operates as a Developer of a percutaneous device for treating tricuspid regurgitation. CroiValve has raised $52.1M in funding from investors like Halo Business Angel Network, Irrus Investments and Broadview Ventures. The company has 109 active competitors, including 49 funded and 28 that have exited. Its top competitors include companies like Shockwave Medical, Cardiac Dimensions and MicroPort CardioFlow Medtech Corporation.

Company Details

Developer of a percutaneous device for treating tricuspid regurgitation. The device seals the gap between the valve leaflets preventing regurgitation. The device is delivered through a vein and into the right heart, restoring the function of the tricuspid valve.

Website: croivalve.com
Social
Email ID: *****@croivalve.com

Key Metrics

Founded Year

2016

Location

Dublin, Ireland

Stage

Series B

Total Funding

$52.1M in 13 rounds

Latest Funding Round

Grant (prize money), Jun 23, 2026, $*****

Investors

Halo Business Angel Network & 22 more

Ranked

7^th among 109 active competitors

Employee Count

56 as on Aug 31, 2026

Similar Companies

Shockwave Medical & 142 more

View CroiValve's full profile

CroiValve has raised a total funding of $52.1M over 13 rounds. Its first funding round was on 2018. Its latest funding round was a Grant (prize money) round on Jun 23, 2026 for $*****. 2 investors participated in its latest round. CroiValve has 23 institutional investors.

Here is the list of recent funding rounds of CroiValve:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 23, 2026	2891048	Grant (prize money)	1996493	1633446	1432079	6459782
Jun 23, 2026	2866170	Series B	7025151	3109543	2165541	BGF & 2 more
Jul 02, 2025	1714308	Grant (prize money)	3297329	2516453	9991081	European Innovation Council

Access funding benchmarks and valuations. Sign up today!

View details of CroiValve's funding rounds and investors

The founders of CroiValve are Martin Quinn and Lucy Okeeffe. Lucy Okeeffe is the CEO of CroiValve.

Here are the details of CroiValve's key team members:

Martin Quinn: Co-Founder & CMO of CroiValve. They are also an angel investor in 1 startup and serve on the board of 1 company.
Contact Info: 1 email address
Lucy Okeeffe: Co-Founder & CEO of CroiValve.
Contact Info: 1 email address

View details of CroiValve's Founder profiles and Board Members

CroiValve's employee count trend

CroiValve has 56 employees as of Aug 26. Here is CroiValve's employee count trend over the years:

Uncover CroiValve's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of CroiValve include Shockwave Medical, Cardiac Dimensions and MicroPort CardioFlow Medtech Corporation. Here is the list of Top 10 competitors of CroiValve, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Shockwave Medical 2009, Santa Clara (United States), Acquired	Developer of cardiovascular balloon dilation catheters	$148M	Sofinnova Partners, Venrock & 9 others	65/100
2nd	Cardiac Dimensions 2001, Kirkland (United States), Series E	Developer of invasive cardiac implants for heart failure	$261M	Life Sciences Partners, Lumira Ventures & 20 others	63/100
3rd	MicroPort CardioFlow Medtech Corporation 2015, Pudong (China), Public	Developer of smart medical devices for patients with heart valve diseases	$132M	Lake Bleu Capital, CICC & 10 others	63/100
4th	Peijia Medical Technologies 2012, Suzhou (China), Public	Developer of medical devices for the treatment of cardiac and cerebrovascular diseases	$110M	Lilly Asia Ventures, SDIC Innovation & 9 others	63/100
5th	JenaValve Technology 2006, Irvine (United States), Acquired	Provider of pericardial transcatheter aortic valve replacement and delivery system	$364M	Sunstone, Valiance Asset Management & 19 others	62/100
6th	Venus MedTech 2009, Hangzhou (China), Public	Transcatheter aortic valves	$37M	DCP, HongShan & 6 others	61/100
7th	CroiValve 2016, Dublin (Ireland), Series B	Developer of a percutaneous device for treating tricuspid regurgitation	$52.1M	Irrus Investments, European Innovation Council ... & 21 others	58/100
8th	TRiCares 2013, Aschheim (Germany), Series D	Developer of a minimally invasive tricuspid valve replacement system. This system is designed to treat tricuspid regurgitation, a serious heart condition, without the need for open-heart surgery. The company focuses on developing a safe and effective solution to address the limitations of existing treatment approaches. It is developing a catheter-based system for tricuspid valve replacement. The company's efforts include clinical trials and securing funding to support further development and clinical milestones.	$103M	415 CAPITAL, Lifeblood Capital & 10 others	57/100
9th	Foldax 2006, Salt Lake City (United States), Series D	Developer of bio-polymeric heart valves to treat aortic, mitral, and tricuspid valve diseases	$43.7M	MemorialCare Innovation Fund, BioStar Capital ... & 3 others	56/100
10th	HighLife Medical 2010, Paris (France), Series B	Developer of trans-catheter mitral valve replacement system	$50.8M	Andera Partners, Sofinnova Partners & 7 others	56/100